Spots Global Cancer Trial Database for Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
Official Title: A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer
Study ID: NCT01772797
Study Description
Brief Summary: The primary purpose of the study is to estimate the maximum tolerated dose of the combination of LDK378 and AUY922. This study will assess the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumor activity of the combination of LDK378 and AUY922 in ALK-rearranged non-small cell lung cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Colorado Dept. of Anschutz Cancer (3), Aurora, Colorado, United States
Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia, Pennsylvania, United States
University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Barcelona, Catalunya, Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
